Campbell McInnes

7PUBLICATIONS
5CO-AUTHORS
Molecular targetsGene and molecular therapyBasic pharmacologyCheminformatics and quantitative structure-activity relationshipsClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 16, 2025
Structural regulation of PLK1 activity: implications for cell cycle function and drug discovery.

Danda Chapagai, Klaus Strebhardt, Michael D Wyatt

|Dec 12, 2024
Overcoming Resistance to FLT3-ITD Therapeutics.

Campbell McInnes

|Jul 11, 2023
Structural Basis for Variations in Polo-like Kinase 1 Conformation and Intracellular Stability Induced by ATP-Competitive and Novel Noncompetitive Abbapolin Inhibitors.

Danda Chapagai, George Merhej, Campbell McInnes

|Feb 03, 2022
A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.

Li Zhang, Chen Cheng, Jing Li

|Jul 02, 2021
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.

Danda Chapagai, Gurusankar Ramamoorthy, Jessy Varghese

|Apr 02, 2020
Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.

Merissa Baxter, Danda Chapagai, Sandra Craig

Pageof 2

Frequent Collaborators

4 joint publications

Michael D Wyatt

3 joint publications

Danda Chapagai

1 joint publications

Igor B Roninson

1 joint publications

Mengqian Chen